Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Qiagen ( (QGEN) ) has shared an announcement.
Qiagen has disclosed a notification from the Dutch financial regulator AFM showing that BlackRock, Inc. and various affiliated entities together hold a significant position in Qiagen shares and related derivatives. The filing indicates that BlackRock’s total capital interest in Qiagen stands at 10.29% and its voting rights at 11.43%, mostly through indirect real holdings with a smaller portion in potential positions via contracts for difference.
The announcement underscores the presence of a major global asset manager among Qiagen’s largest shareholders, which may support liquidity in the stock and signal institutional confidence in the company. Qiagen emphasized that it is not responsible for the accuracy of the AFM notification, which was reproduced from the regulator’s public register in line with German securities disclosure requirements.
The most recent analyst rating on (QGEN) stock is a Hold with a $47.00 price target. To see the full list of analyst forecasts on Qiagen stock, see the QGEN Stock Forecast page.
More about Qiagen
Qiagen N.V. is a Netherlands-based life sciences company specializing in sample and assay technologies for molecular diagnostics, applied testing, academic research, and pharmaceutical development. Its shares are listed on multiple European exchanges as well as the NYSE and Swiss markets, giving the company broad access to international capital and a diverse investor base.
Average Trading Volume: 2,335,786
Technical Sentiment Signal: Strong Sell
Current Market Cap: $8.5B
Find detailed analytics on QGEN stock on TipRanks’ Stock Analysis page.